- Home
- SABR vs ARQT Comparison
SABR vs ARQT Comparison
Compare SABR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- ARQT
- Stock Information
- Founded
- SABR 2006
- ARQT 2016
- Country
- SABR United States
- ARQT United States
- Employees
- SABR N/A
- ARQT N/A
- Industry
- SABR Computer Software: Programming Data Processing
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- SABR Technology
- ARQT Health Care
- Exchange
- SABR Nasdaq
- ARQT Nasdaq
- Market Cap
- SABR 1.3B
- ARQT 1.1B
- IPO Year
- SABR 2014
- ARQT 2020
- Fundamental
- Price
- SABR $4.52
- ARQT $13.02
- Analyst Decision
- SABR Hold
- ARQT Strong Buy
- Analyst Count
- SABR 4
- ARQT 6
- Target Price
- SABR $3.25
- ARQT $17.00
- AVG Volume (30 Days)
- SABR 3.7M
- ARQT 2.3M
- Earning Date
- SABR 02-20-2025
- ARQT 02-25-2025
- Dividend Yield
- SABR N/A
- ARQT N/A
- EPS Growth
- SABR N/A
- ARQT N/A
- EPS
- SABR N/A
- ARQT N/A
- Revenue
- SABR $3,029,565,000.00
- ARQT $138,708,000.00
- Revenue This Year
- SABR $6.34
- ARQT $217.37
- Revenue Next Year
- SABR $5.08
- ARQT $55.64
- P/E Ratio
- SABR N/A
- ARQT N/A
- Revenue Growth
- SABR 4.19
- ARQT 182.84
- 52 Week Low
- SABR $1.81
- ARQT $6.99
- 52 Week High
- SABR $4.63
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- SABR 78.07
- ARQT 50.16
- Support Level
- SABR $3.39
- ARQT $11.13
- Resistance Level
- SABR $3.60
- ARQT $13.62
- Average True Range (ATR)
- SABR 0.19
- ARQT 1.04
- MACD
- SABR 0.10
- ARQT 0.08
- Stochastic Oscillator
- SABR 92.25
- ARQT 67.26
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2023 revenue, split between distribution (78% of segment sales) and airline IT solutions (22%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.